Considering propranolol’s strong potency as a BChE inhibitor and its likely cholinergic-enhancing effects in vivo, future studies should carefully explore the possibility that propranolol’s dual pharmacodynamic actions could contribute to the observed clinical improvements, not only in this context but also in other cognitive disorders, such as Alzheimer’s and Lewy body dementia (Minger et al., 2000; Cummings et al., 2024; Saint-Georges et al., 2025). This evidence concerns the gene BCHE and Cognitive impairment.